TABLE 6.
Ongoing clinical trials of combined anti-epigenetic drugs and anti-metabolism drugs.
| Identifier | Start year | Combination therapy | Conditions | Phase | Enrollment | |
|---|---|---|---|---|---|---|
| Anti-epigenetics drug | Anti-metabolism drug | |||||
| NCT02719574 | 2016 | Azacitidine | FT-2102 | AML/MDS | I/II | 336 |
| NCT02677922 | 2016 | Azacitidine | AG-120 | AML | I/II | 131 |
| NCT03173248 | 2017 | Azacitidine | AG-120 | AML | III | 148 |
| NCT03471260 | 2018 | Azacitidine | AG-120 | Hematologic malignancies | I/II | 30 |
| NCT03683433 | 2018 | Azacitidine | AG-221 | AML | II | 50 |
| NCT03684811 | 2018 | Azacitidine | FT-2102 | Solid tumors and gliomas | I/II | 200 |
| NCT04774393 | 2021 | Decitabine | AG-120/AG-221 | AML | I/II | 84 |
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; DNMT, inhibitors: Azacitidine; Decitabine. IDH, inhibitors: AG-120 (Ivosidenib); AG-221 (Enasidenib); FT-2102.